ChAdOx1-S[recombinant] (COVID-19 Vaccine AstraZeneca) - Food and Drug Administration

ChAdOx1-S[recombinant] VAXZEVRIA (COVID-19 Vaccine AstraZeneca)

On 28 January 2021, the Food and Drug Administration (FDA) issued authorization (amended on 10 March 2022) granting AstraZeneca Pharmaceuticals (Phils.) Inc. the emergency use approval of COVID-19 vaccine ChAdOx1-S[recombinant] Vaxzevria (COVID-19 Vaccine AstraZeneca).

Product Information Patient Information Leaflet

For more information on reporting side effects, click here.

Shares